Spermosens

0.01 SEK

0.00 %

Less than 1K followers

SPERM

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

+3.33 %

-16.22 %

-27.91 %

-53.73 %

-48.33 %

-97.22 %

-

-99.36 %

Spermosens are active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.

Market cap

19.67M SEK

Turnover

18K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

11.2

2026

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release12/9/2025, 7:45 AM

Spermosens shares progress and plans for partner-driven commercialization

Regulatory press release12/8/2025, 12:41 PM

Spermosens announces outcome of exercise of warrants series TO 4

Regulatory press release11/24/2025, 4:12 PM

Spermosens announces last day of trading for warrants of series TO 4

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/18/2025, 9:21 AM

Spermosens receives patent approval in China

Regulatory press release11/12/2025, 8:04 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

Regulatory press release11/4/2025, 4:21 PM

Spermosens receives patent approval in Israel

Regulatory press release11/3/2025, 11:31 AM

Spermosens receives patent approval in Mexico

Regulatory press release10/22/2025, 9:17 AM

Spermosens receives patent approval in Canada

Regulatory press release8/20/2025, 7:38 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2025

Press release8/7/2025, 6:30 AM

Spermosens provides status update following successful clinical study

Regulatory press release6/17/2025, 12:16 PM

Spermosens announces outcome of exercise of warrants series TO 5

Regulatory press release6/16/2025, 9:15 AM

Spermosens AB Announces Results from Annual General Meeting on 16 June 2025

Regulatory press release6/13/2025, 11:04 AM

Chairman and CEO of Spermosens exercise TO5 warrants

Regulatory press release6/11/2025, 10:48 AM

Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked

Regulatory press release6/5/2025, 7:09 PM

Spermosens: The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products

Regulatory press release6/5/2025, 10:27 AM

Last day of trading in warrants series TO 5 in Spermosens is 12 June 2025

Regulatory press release6/2/2025, 6:45 AM

Spermosens: The subscription price for warrants of series TO 5 has been determined - the exercise period begins today

Regulatory press release5/26/2025, 10:06 AM

Spermosens publishes annual report for the financial year 2024

Regulatory press release5/15/2025, 6:51 AM

Spermosens: NOTICE OF ANNUAL GENERAL MEETING 2025 IN SPERMOSENS AB (publ)

Regulatory press release5/7/2025, 7:10 AM

Spermosens AB (publ)INTERIM REPORT JANUARY - MARCH 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.